This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Source of effectiveness data
Evidence for final outcomes were based on opinion.
Modelling
A model was used in estimating both lifetime benefits and costs associated with screening. The model used populationwide data on prevalence and incidence rates of disease for the USA, and included costs and effects associated with screening, further intensive diagnostic follow-up for positive cases, and treatment of disease. Such calculations started from the age 25.
Methods used to derive estimates of effectiveness
Estimates of effectiveness were based on authors' assumptions.
Estimates of effectiveness and key assumptions
(2) the lifetime risk of colorectal cancer in general population is 6%; (3) the median survival from colorectal cancer is 8 years;
(4)penetrance of the HNPCC genotype is 80%; (5) the median age of diagnosis of HNPCC-related colorectal cancer is 45 years of age; (6)the average number of years of life gained through the intervention is 20 years (9.76 years when discounted at 5%); and, (7)implicit in the base case calculations,a 100% rate of accuracy of genetic testing.
Measure of benefits used in the economic analysis
Life-years saved (discounted) was the outcome measure used in the economic analysis, the estimate being derived from a model.
Direct costs
Whilst costs were discounted, the quantities of resource use were not reported separately from the costs. Costs considered in the analysis were as follows: the unit cost of genetic testing for HNPCC, including counselling, and the diagnostic-treatment regimen (periodic colonoscopy and colonoscopic removal of detected adenomas) that would follow a positive test and treatment of disease given no intervention. The source of some of these costs was information from previously published studies from 1991 and 1994. Total costs were estimated using a model. On the other hand, the costs associated with colonoscopy-induced perforation of the large bowel were not considered. The price year was not clearly stated.
Currency

US dollars ($).
Sensitivity analysis
One way and multi-way sensitivity analyses were carried out on both the effectiveness and cost data. The main parameters investigated were the prevalence rate, the cost of genetic testing, the life expectancy of the average person treated for HNPCC, the penetrance of the HNPCC genotype, and the discount rate.
Estimated benefits used in the economic analysis
The estimated benefits were not explicitly presented in the paper. However, following the formulae provided by the authors, one can calculate the implicit estimates in the results actually reported. The undiscounted life years gained per patient screened ranged from 0.00608 to 0.184. The corresponding figure for discounted life-years gained with screening relative to no screening ranged from 0.00297 to 0.0898. The side-effects of treatment were not considered in this analysis.
Cost results
Although not stated, one can follow the authors in calculating the total cost estimates per patient screened, as above. The expected discounted cost per patient screened ranged from $989.4 to $1,041.9 depending on the prevalence of HNPCC gene in the population.
Synthesis of costs and benefits
The costs per life-year saved (with costs and benefits both discounted at 5%) ranged from $333,000 to $11,000
